The probiotic supplementation reduced inflammation in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders that plaques women today. One of the underlying factors associated with the development of PCOS is elevated inflammation. However, the application of available nutraceutical therapies remains relatively unknown and thus is the focus of the current study. In this manner, we evaluated the effects of probiotic supplement on clinical and immunological parameters of PCOS. Our randomized-control trial, four strains of Lactobacillus for a probiotic group and the equivalent dosage with maltodextrin was used as the placebo. To further understand the impacts of immunological parameters towards inflammation in PCOS, we measured interleukin (IL) 6, 10, TNF-alpha, hs-CRP and clinical manifestations before and after the trial. The probiotic supplementation resulted in a significant increase in IL-10 levels compared with the placebo, after the intervention. However, in both groups, there was a significant decrease in hs-CRP and IL-6 levels. Probiotic supplementation does not make any significant changes in the TNF-alpha levels. This study observed that Lactobacillus supplementation modulates inflammation in PCOS patients.